ASLAN Pharmaceuticals Income Statement

Financials in millions IDR. Fiscal year is January - December.

Millions IDR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	927,617	920,552	931,006	670,120	627,717	83,599
Revenue Growth (YoY)	-1.93%	-1.12%	38.93%	6.75%	650.87%	-
Cost of Revenue	529,301	519,624	554,129	368,904	324,763	88,852
Gross Profit	398,316	400,928	376,877	301,216	302,954	-5,253
Selling, General & Admin	76,870	78,838	70,639	37,390	26,589	20,398
Operating Expenses	76,870	78,838	70,639	37,390	26,589	20,398
Operating Income	321,446	322,090	306,238	263,826	276,365	-25,652
Interest Expense	-64,866	-96,396	-193,499	-178,492	-169,085	-94,762
Interest & Investment Income	159,549	149,228	124,032	136,308	106,437	66,642
Currency Exchange Gain (Loss)	26,141	2,300	2,561	-40,178	1,168	4,584
Other Non Operating Income (Expenses)	-9,470	-9,637	-3,534	525	-1,043	-1,996
EBT Excluding Unusual Items	432,800	367,585	235,799	181,989	213,842	-51,185
Asset Writedown	-7,616	-6,339	-1,432	-4,295	-1,671	-4,583
Pretax Income	425,184	361,245	234,367	177,694	212,171	-55,768
Income Tax Expense	75,696	61,625	51,456	25,878	23,522	-2,064
Earnings From Continuing Operations	349,488	299,620	182,910	151,816	188,648	-53,704
Minority Interest in Earnings	-24,882	-10,352	3,857	11,763	-	-
Net Income	324,606	289,269	186,768	163,579	188,648	-53,704
Net Income to Common	324,606	289,269	186,768	163,579	188,648	-53,704
Net Income Growth	83.15%	54.88%	14.18%	-13.29%	-	-
Shares Outstanding (Basic)	15,822	15,496	12,062	10,200	10,200	10,200
Shares Outstanding (Diluted)	15,822	15,496	12,062	10,200	10,200	10,200
Shares Change (YoY)	20.38%	28.47%	18.25%	-	-	-
EPS (Basic)	20.52	18.67	15.48	16.04	18.49	-5.27
EPS (Diluted)	20.51	18.67	15.48	16.04	18.49	-5.27
EPS Growth	52.12%	20.59%	-3.47%	-13.29%	-	-
Free Cash Flow	11,476	-150,433	-166,209	10,704	47,086	-181,379
Free Cash Flow Per Share	0.72	-9.71	-13.78	1.05	4.62	-17.78
Dividend Per Share	4.500	4.500	-	-	-	-
Gross Margin	42.94%	43.55%	40.48%	44.95%	48.26%	-6.28%
Operating Margin	34.65%	34.99%	32.89%	39.37%	44.03%	-30.68%
Profit Margin	34.99%	31.42%	20.06%	24.41%	30.05%	-64.24%
Free Cash Flow Margin	1.24%	-16.34%	-17.85%	1.60%	7.50%	-216.96%
EBITDA	378,490	376,463	346,502	293,232	301,897	-12,843
EBITDA Margin	40.80%	40.89%	37.22%	43.76%	48.09%	-15.36%
D&A For EBITDA	57,044	54,373	40,264	29,406	25,532	12,808
EBIT	321,446	322,090	306,238	263,826	276,365	-25,652
EBIT Margin	34.65%	34.99%	32.89%	39.37%	44.03%	-30.68%
Effective Tax Rate	17.80%	17.06%	21.95%	14.56%	11.09%	-

Updated Dec 1, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.